Psychosomatic aspects of vitiligo. A review of the literature

Cover Page

Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

The active interest of researchers in the topic of vitiligo is due to both the potential for optimizing the treatment of chronic dermatosis of unknown etiology and the high psychosocial significance of the problem, which goes beyond the purely medical sphere.

The review deals with psychosomatic aspects of vitiligo: stressful manifestations; stigmatization and quality of life of patients with vitiligo; nosogenic (secondary) and comorbid vitiligo mental disorders; the article considers complex approaches to therapy, taking into account psychosomatic factors. The literature was searched in the following databases: PubMed, Scopus, MedLine, Embase, Cochrane, Russian State Library, the Sechenov Central Science Medical Library.

It seems extremely relevant and promising to develop a clinical typology of comorbid vitiligo psychosomatic disorders with the development of clinical recommendations for the identification, routing and therapy of an extensive contingent of patients with chronic dermatosis.

About the authors

Amer Kurdi Mohammed Al-Janabi

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: dr.mohammedkurdi@gmail.com
ORCID iD: 0009-0000-4346-3409
SPIN-code: 5295-0314

Graduate Student

Russian Federation, 4/1 Bolshaia Pirogovskaia street, 119435 Moscow

Igor Yu. Dorozhenok

I.M. Sechenov First Moscow State Medical University (Sechenov University); Mental Health Research Center of the Russian Academy of Medical Sciences

Author for correspondence.
Email: idoro@bk.ru
ORCID iD: 0000-0003-1613-2510
SPIN-code: 8701-7958

MD, Cand. Sci. (Med.), Assistant Professor

Russian Federation, 4/1 Bolshaia Pirogovskaia street, 119435 Moscow; Moscow

Konstantin M. Lomonosov

I.M. Sechenov First Moscow State Medical University (Sechenov University)

Email: lamclinic@yandex.ru
ORCID iD: 0000-0002-4580-6193
SPIN-code: 4784-9730

MD , Dr. Sci. (Med.), Professor

Russian Federation, 4/1 Bolshaia Pirogovskaia street, 119435 Moscow

References

  1. Ezzedine K, Eleftheriadou V, Whitton M, van Geel N. Vitiligo. Lancet. 2015;386(9988):74–84. doi: 10.1016/S0140-6736(14)60763-7
  2. Katz EL, Harris JE. Translational research in Vitiligo. Front Immunol. 2021;(12):624517. doi: 10.3389/fimmu.2021.624517
  3. Picardo M, Dell’Anna ML, Ezzedine K, et al. Vitiligo. Nat Rev Dis Primers. 2015;(1):15011. doi: 10.1038/nrdp.2015.11
  4. Rakhimov US, Mukhamadieva KM, Ismatulloeva SS. Neurovegetative disorders in vitiligo pathogenesis. Avicennas Bulletin. 2017;19(4):550–555. (In Russ). doi: 10.25005/2074-0581-2017-19-4-550-555
  5. Tang L, Li F, Xu F, et al. Prevalence of vitiligo and associated comorbidities in adults in Shanghai, China: A community-based, cross-sectional survey. Ann Palliat Med. 2021;10(7):8103–8111. doi: 10.21037/apm-21-1738
  6. Frisoli ML, Essien K, Harris JE. Vitiligo: Mechanisms of pathogenesis and treatment. Annu Rev Immunol. 2020;(38):621–648. doi: 10.1146/annurev-immunol-100919-023531
  7. Gürpınar A, Günaydın S, Kılıç C, Karaduman A. Association of serum cortisol and dehydroepiandrosterone sulfate (DHEAS) levels with psychological stress in patients with vitiligo. Turk J Med Sci. 2019;49(3):832–837. doi: 10.3906/sag-1812-84
  8. Ning X, Zhang Y, Wang W, et al. Evaluation of the behavioral and psychological symptoms in patients with vitiligo in China. Psychol Res Behav Manag. 2022;(15):2107–2116. doi: 10.2147/PRBM.S370445
  9. Varzhapetyan AA, Dorozhenok IY, Lomonosov KM. Vitiligo and comorbid psychosomatic disordes. Russ J Skin Venereal Dis. 2019;22(1-2):33–38. (In Russ).
  10. Dahir AM, Thomsen SF. Comorbidities in vitiligo: Comprehensive review. Int J Dermatol. 2018;57(10):1157–1164. doi: 10.1111/ijd.14055
  11. Bonotis K, Pantelis K, Karaoulanis S, et al. Investigation of factors associated with health-related quality of life and psychological distress in vitiligo. J Dtsch Dermatol Ges. 2016;14(1):45–49. doi: 10.1111/ddg.12729
  12. Silverberg JI, Silverberg NB. Vitiligo disease triggers: Psychological stressors preceding the onset of disease. Cutis. 2015;95(5):255–262.
  13. Morrison B, Burden-Teh E, Batchelor JM, et al. Quality of life in people with vitiligo: A systematic review and meta-analysis. Br J Dermatol. 2017;177(6):e338–339. doi: 10.1111/bjd.15933
  14. Yang Y, Zapata L, Rodgers C, et al. Quality of life in patients with vitiligo using the short Form-36. Br J Dermatol. 2017;177(6):1764–1766. doi: 10.1111/bjd.15936
  15. Ezzedine K, Eleftheriadou V, Jones H, et al. Psychosocial effects of vitiligo: A systematic literature review. Am J Clin Dermatol. 2021;22(6):757–774. doi: 10.1007/s40257-021-00631-6
  16. Sangma LN, Nath J, Bhagabati D. Quality of life and psychological morbidity in vitiligo patients: A study in a teaching hospital from North-East India. Indian J Dermatol. 2015;60(2):142–146. doi: 10.4103/0019-5154.152508
  17. Sarkar S, Sarkar T, Sarkar A, Das S. Vitiligo and psychiatric morbidity: A profile from a vitiligo clinic of a rural-based tertiary care center of eastern India. Indian J Dermatol. 2018;63(4):281–284.doi: 10.4103/ijd.IJD_142_18
  18. Osinubi O, Grainge MJ, Hong L, et al. The prevalence of psychological comorbidity in people with vitiligo: A systematic review and metaanalysis. Br J Dermatol. 2018;178(4):863–878. doi: 10.1111/bjd.16049
  19. Simons RE, Zevy DL, Jafferany M. Psychodermatology of vitiligo: Psychological impact and consequences. Dermatologic Therapy. 2020;33(3):e13418. doi: 10.1111/dth.13418
  20. Wang G, Qiu D, Yang H, Liu W. The prevalence and odds of depression in patients with vitiligo: A meta-analysis. J Eur Acad Dermatol Venereol. 2018;32(8):1343–1351. doi: 10.1111/jdv.14739
  21. Kussainova A, Kassym L, Akhmetova A, et al. Vitiligo and anxiety: A systematic review and meta-analysis. PLoS One. 2020;15(11):e0241445. doi: 10.1371/journal.pone.0241445
  22. Khojah HM, Alharbi AG, Alshaeri AA, et al. Impact of narrow-band ultraviolet B radiation therapy on the quality of life of patients with vitiligo. J Taibah Univ Med Sci. 2021;16(6):843e848. doi: 10.1016/j.jtumed.2021.04.012
  23. Cadmus SD, Riddle AO, Sebastian KR, et al. Psychosocial and quality-of-life factors associated with depigmentation therapy for vitiligo. Arch Dermatol Res. 2023;315(8):2283–2288. doi: 10.1007/s00403-023-02595-5
  24. Al-Shobaili HA. Treatment of vitiligo patients by excimer laser improves patients’ quality of life. J Cutan Med Surg. 2015;19(1):50–56. doi: 10.2310/7750.2014.14002
  25. Olisova OY, Pinson IY, Myzina KA, Garanyan LG. Combined phototherapy method for vitiligo. Russ J Skin Venereal Dis. 2017;20(4):238–242. (In Russ). doi: 10.18821/1560-9588-2017-20-4-238-242
  26. Tavitova AR, Lomonosov KM. Comparative study of the effectiveness of combination therapy of vitiligo with methotrexate in combination with medium-wave narrow-band therapy UVB-311 nm and monotherapy UVB-311 nm. Russ J Skin Venereal Dis. 2021;24(5):451–459. (In Russ). doi: 10.17816/dv88864
  27. Cupertino F, Niemeyer-Corbellini JP, Ramos ES. Psychosomatic aspects of vitiligo. Clin Dermatol. 2017;35(3):292–297. doi: 10.1016/j.clindermatol.2017.01.001
  28. Revankar RR, Revankar NR, Balogh EA, et al. Cognitive behavior therapy as dermatological treatment: A narrative review. Int J Womens Dermatol. 2022;8(4):e068. doi: 10.1097/JW9.0000000000000068
  29. Rzepecki AK, McLellan BN, Elbuluk N. Beyond traditional treatment: The importance of psychosocial therapy in vitiligo. J Drugs Dermatol. 2018;17(6):688–691.

Copyright (c) 2023 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies